- Conditions
- Hodgkin Disease, Lymphoma, Lymphoma, Non-Hodgkin, Immune System Diseases, Immunoproliferative Disorders, Lymphatic Diseases, Lymphoproliferative Disorders, Neoplasms, Neoplasms by Histologic Type
- Interventions
- ATLCAR.CD30 cells
- Drug
- Lead sponsor
- UNC Lineberger Comprehensive Cancer Center
- Other
- Eligibility
- 3 Years and older
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2037
- U.S. locations
- 2
- States / cities
- Chapel Hill, North Carolina • Winston-Salem, North Carolina
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 24
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Alcohol Use Disorder, Human Immunodeficiency Virus
- Interventions
- 4 week prebiotic consumption, 4 week placebo consumption
- Dietary Supplement · Other
- Lead sponsor
- Rush University Medical Center
- Other
- Eligibility
- 45 Years to 75 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2029
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- HIV Infections
- Interventions
- Tipranavir/Ritonavir, Rosuvastatin
- Drug
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 29 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2007 – 2008
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Multiple Sclerosis
- Interventions
- No intervention, just collect blood samples and CSF samples
- Other
- Lead sponsor
- Thomas Jefferson University
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 96 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2023
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Lymphoma, Non-Hodgkin
- Interventions
- SB-485232, Rituximab
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2010
- U.S. locations
- 2
- States / cities
- Chicago, Illinois • Indianapolis, Indiana
- Conditions
- Hematological Malignancies, Myelodysplastic Syndrome, Leukemia, Lymphoma
- Interventions
- Mycophenolate Mofetil (MMF), Thymoglobulin, Sirolimus, Stem Cell Transplant
- Drug · Procedure
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2010
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Arthritis, Rheumatoid
- Interventions
- peficitinib, Placebo
- Drug
- Lead sponsor
- Astellas Pharma Global Development, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 289 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 19
- States / cities
- Birmingham, Alabama • La Jolla, California • Palm Desert, California + 16 more
- Conditions
- Asthma
- Interventions
- FLOVENT™ DISKUS™ 100 mcg BID, ADVAIR™ DISKUS™ 100/50 mcg BID
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 4 Years to 11 Years
- Enrollment
- 339 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010
- U.S. locations
- 38
- States / cities
- Tucson, Arizona • Bakersfield, California • Fresno, California + 33 more
- Conditions
- Healthy
- Interventions
- gp140, 50 mcg, gp140, 50 mcg + Adjuvant, gp140, 250 mcg, gp140, 250 mcg + Adjuvant, Placebo
- Biological · Drug
- Lead sponsor
- Crucell Holland BV
- Industry
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2016
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Chlamydia, Gonorrhea, Hiv, Syphilis
- Interventions
- Chlamydia, gonorrhea, syphilis, and HIV screening
- Other
- Lead sponsor
- Tulane University
- Other
- Eligibility
- 15 Years to 26 Years
- Enrollment
- 2,322 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2029
- U.S. locations
- 1
- States / cities
- New Orleans, Louisiana
- Conditions
- HIV Infections, Sexually Transmitted Diseases, Viral, Syphilis
- Interventions
- mLab App Plus
- Behavioral
- Lead sponsor
- Columbia University
- Other
- Eligibility
- 18 Years to 39 Years · Male only
- Enrollment
- 40 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2024
- U.S. locations
- 2
- States / cities
- New York, New York • Nashville, Tennessee
- Conditions
- Skin and Soft Tissue Infections, Hiv, Hepatitis C, Bloodstream Infection
- Interventions
- ASAP
- Behavioral
- Lead sponsor
- University of Arizona
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 18 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- Tucson, Arizona
- Conditions
- Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Cutaneous B-cell Non-Hodgkin Lymphoma, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Intraocular Lymphoma, Nodal Marginal Zone B-cell Lymphoma, Peripheral T-cell Lymphoma, Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Diffuse Mixed Cell Lymphoma, Recurrent Adult Diffuse Small Cleaved Cell Lymphoma, Recurrent Adult Grade III Lymphomatoid Granulomatosis, Recurrent Adult Hodgkin Lymphoma, Recurrent Adult Immunoblastic Large Cell Lymphoma, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Adult T-cell Leukemia/Lymphoma, Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Mycosis Fungoides/Sezary Syndrome, Recurrent Small Lymphocytic Lymphoma, Refractory Multiple Myeloma, Small Intestine Lymphoma, Splenic Marginal Zone Lymphoma, Waldenström Macroglobulinemia
- Interventions
- bendamustine hydrochloride, dexamethasone, filgrastim, leukapheresis, laboratory biomarker analysis, flow cytometry, etoposide
- Drug · Biological · Procedure + 1 more
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 43 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2010
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Plasma Cell Leukemia, Plasma Cell Myeloma
- Interventions
- Autologous Hematopoietic Stem Cell Transplantation, Elotuzumab, Laboratory Biomarker Analysis, Lenalidomide, Melphalan, Natural Killer Cell Therapy, Umbilical Cord Blood-Derived Lymphocyte Therapy
- Procedure · Biological · Other + 1 more
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 72 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2024
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Cutaneous T-cell Lymphoma, Sezary Syndrome, Mycosis Fungoides
- Interventions
- Not listed
- Lead sponsor
- University of Pittsburgh
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2006
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Stage II Multiple Myeloma, Stage III Multiple Myeloma, Refractory Plasma Cell Neoplasm
- Interventions
- autologous tumor cell vaccine, keyhole limpet hemocyanin, melphalan, sargramostim
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Timeline
- 1995 – 2007
- U.S. locations
- 3
- States / cities
- Little Rock, Arkansas • Bethesda, Maryland
- Conditions
- Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus, Hypercholesterolemia
- Interventions
- simvastatin or ezetimibe
- Drug
- Lead sponsor
- Medical College of Wisconsin
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 57 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2013
- U.S. locations
- 1
- States / cities
- Milwaukee, Wisconsin
- Conditions
- Soy Allergy
- Interventions
- Oral food challenge
- Other
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 6 Months to 40 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2018
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- Asthma, Allergic
- Interventions
- Bronchoscopy/BAL, Airway Brushing
- Procedure
- Lead sponsor
- Andrew D. Luster, M.D.,Ph.D.
- Other
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 37 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2027
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Plasma Cell Myeloma
- Interventions
- Daratumumab, Dexamethasone, Ixazomib Citrate, Laboratory Biomarker Analysis, Lenalidomide, Questionnaire Administration
- Biological · Drug · Other
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2022
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Asthma, Exercise-Induced Bronchoconstriction
- Interventions
- Lyprinol, Placebo (Olive Oil)
- Dietary Supplement
- Lead sponsor
- Indiana University
- Other
- Eligibility
- 18 Years to 30 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012
- U.S. locations
- 1
- States / cities
- Bloomington, Indiana
- Conditions
- HIV Infections
- Interventions
- ATV, RTV, Tenofovi-Emtricitabine (TDF/FTC) tablet, LPV
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,057 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2008
- U.S. locations
- 8
- States / cities
- Phoenix, Arizona • Laguna Beach, California • Washington D.C., District of Columbia + 5 more
- Conditions
- Monoclonal Gammopathy of Undetermined Significance, Smoldering Multiple Myeloma
- Interventions
- Metformin XR, Placebo
- Drug · Other
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 7
- States / cities
- Boston, Massachusetts • Brighton, Massachusetts • Methuen, Massachusetts + 3 more
- Conditions
- HIV Infections, Histoplasmosis, Blastomycosis
- Interventions
- Itraconazole, Amphotericin B
- Drug
- Lead sponsor
- Janssen, LP
- Industry
- Eligibility
- 13 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 9
- States / cities
- Birmingham, Alabama • Little Rock, Arkansas • Atlanta, Georgia + 4 more